Novel approaches to fight Streptococcus pneumoniae
Beatriz Maestro1, Jesús M Sanz
1Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Av. Universidad, s/n. 03202 Elche (Alicante), Spain. bmaestro@umh.es
Recent Patents on Anti-Infective Drug Discovery
|January 29, 2008
Summary
Streptococcus pneumoniae causes severe diseases like pneumonia and meningitis, especially in vulnerable groups. New patented methods for diagnosis, prevention, and treatment are emerging to combat this pathogen and its antibiotic resistance.
Area of Science:
- Microbiology
- Infectious Diseases
- Vaccinology
Background:
- Streptococcus pneumoniae is a major global pathogen causing pneumonia, meningitis, and bacteremia.
- Pneumococcal disease disproportionately affects young children, the elderly, and immunocompromised individuals.
- Current strategies include vaccination and benzylpenicillin, but serotype diversity and antibiotic resistance pose challenges.
Purpose of the Study:
- To review patented methods for the prevention, diagnosis, and treatment of pneumococcal diseases.
- To highlight advancements in combating Streptococcus pneumoniae infections.
- To discuss novel approaches addressing antibiotic resistance and vaccine development.
Main Methods:
- Review of recent patents related to Streptococcus pneumoniae.
- Analysis of new diagnostic techniques, such as PCR-derived methods.
- Examination of novel therapeutic and preventative strategies, including new antibiotics and protein-based vaccines.
Main Results:
- Patents reveal advancements in PCR-based diagnostics for S. pneumoniae.
- New antibiotics from fluoroquinolone and tetracycline families are patented.
- Protein-based vaccines targeting surface-associated virulence proteins are under development.
Conclusions:
- Emerging patented technologies offer improved diagnostics and treatments for pneumococcal infections.
- Novel antibiotics and protein-based vaccines are crucial for overcoming antibiotic resistance and serotype diversity.
- Continued innovation in patented methods is essential for controlling Streptococcus pneumoniae globally.
Related Concept Videos
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:27Streptococcal Pharyngitis
Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...